MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells
Sign Up to like & getrecommendations! Published in 2020 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-020-02456-x
Abstract: Background Glioblastoma (GB) remains an incurable and deadly brain malignancy that often proves resistant to upfront treatment with temozolomide. Nevertheless, temozolomide remains the most commonly prescribed FDA-approved chemotherapy for GB. The DNA repair protein methylguanine-DNA… read more here.
Keywords: cdk inhibitor; inhibitor; mgmt inhibitor; tgf inhibitor ... See more keywords
Reducing Chemo-/Radioresistance to Boost the Therapeutic Efficacy against Temozolomide-Resistant Glioblastoma.
Sign Up to like & getrecommendations! Published in 2022 at "ACS applied materials & interfaces"
DOI: 10.1021/acsami.2c12348
Abstract: Chemo-/radioresistance is the most important reason for the failure of glioblastoma (GBM) treatment. Reversing the chemo-/radioresistance of GBM for boosting therapeutic efficacy is very challenging. Herein, we report a significant decrease in the chemo-/radioresistance of… read more here.
Keywords: reducing chemo; chemo radioresistance; temozolomide resistant; therapeutic efficacy ... See more keywords